Lirafugratinib Expands FGFR2 Cholangiocarcinoma Options

The approval defines a molecularly selected population

Lirafugratinib is now a targeted option for adults with cholangiocarcinoma that is unresectable and locally advanced or metastatic, has progressed after prior treatment, and harbors an FGFR2 fusion or another qualifying rearrangement. The alteration must be identified using an FDA-approved test.

Those criteria are not interchangeable. The approval does not cover resectable disease, first-line treatment, pediatric patients or cholangiocarcinoma without an eligible FGFR2 rearrangement. It also should not be generalized automatically to every result described on a sequencing report as an “FGFR2 alteration.” Point mutations, amplifications and variants of uncertain significance are biologically distinct from the fusions and rearrangements specified in the indication.

FGFR2 fusions occur predominantly in intrahepatic cholangiocarcinoma. Even so, anatomic classification alone cannot identify an eligible patient. Broad molecular profiling—ideally performed early enough to inform later treatment decisions—is needed to find the relatively small subgroup for whom FGFR-directed therapy is relevant.

The practical change is therefore twofold: another selective FGFR2 inhibitor is available after prior systemic therapy, and failure to obtain adequate molecular testing may now prevent an eligible patient from being considered for an approved treatment.

Evidence came from a single-arm clinical program

The approval was supported by ReFocus, a multicenter, open-label, nonrandomized study of lirafugratinib, previously known as RLY-4008, in advanced solid tumors with FGFR2 alterations. The regulatory efficacy population comprised previously treated patients with unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement who had not previously received an FGFR inhibitor.

The FDA assessed antitumor activity using objective response rate and duration of response, determined by blinded independent central review under standard radiographic response criteria. There was no placebo, chemotherapy or active targeted-treatment comparator.

These findings show clinically meaningful tumor shrinkage in a molecularly defined, previously treated population. They do not establish that lirafugratinib improves overall survival, progression-free survival or quality of life relative to another FGFR inhibitor or to chemotherapy. A response-based, single-arm dataset cannot support those comparative conclusions.

Interpret safety through the prescribing information rather than efficacy results alone. FGFR inhibition can produce ocular toxicity, hyperphosphatemia and other treatment-related adverse effects; the label describes the required assessments, dose modifications and circumstances in which treatment should be withheld or discontinued. Embryo-fetal risk is also relevant when counseling patients with reproductive potential.

Where lirafugratinib fits after prior therapy

The approved setting is after earlier systemic treatment, not as a substitute for established first-line therapy. For an adult whose advanced cholangiocarcinoma progresses after prior treatment, the next decision should incorporate tumor location, performance status, organ function, previous toxicities, treatment goals and the complete genomic report.

The wording “previously treated” is important, but treatment history requires closer examination than a simple line count. The pivotal efficacy population was FGFR inhibitor-naive. Evidence is therefore strongest for patients who have received prior systemic therapy but have not already been exposed to an FGFR inhibitor.

For patients previously treated with pemigatinib, futibatinib or another FGFR-directed agent, the FDA approval does not by itself demonstrate that switching to lirafugratinib will overcome acquired resistance. Some resistance mechanisms are inhibitor-specific, whereas others may confer broader cross-resistance. Clinical benefit in that setting remains less certain and should not be inferred from results in FGFR inhibitor-naive participants.

Treatment selection also cannot be reduced to the presence of an FGFR2 fusion. Other actionable findings, coexisting genomic changes, comorbidities, drug interactions, access and patient preferences may affect the relative suitability of available options. The approval expands choice; it does not establish a preferred sequence among all approved FGFR inhibitors.

Testing quality determines who can be considered

A report should identify the fusion or rearrangement and provide enough information to determine whether it meets the approved indication. Testing strategies differ in their ability to detect rearrangements. DNA-based next-generation sequencing can identify many FGFR2 events, but it may miss some rearrangements because of large intronic regions or technical limitations. RNA-based assays can help confirm expressed fusion transcripts and may resolve an equivocal DNA result.

Adequate tissue remains valuable, although validated liquid-biopsy testing may be considered when tissue is unavailable or insufficient. A negative plasma result does not always exclude an FGFR2 rearrangement because circulating tumor DNA shedding varies. If clinical suspicion remains and suitable tissue can be obtained, tissue-based testing may still be informative.

Plan testing before the disease reaches the point where a rapid treatment decision is required. Obtaining archival tissue, arranging a new biopsy and completing sequencing can take time. Early comprehensive profiling can reduce delays and also identify other findings relevant to treatment or clinical-trial eligibility.

The FDA-approved-test requirement warrants attention. A laboratory report that mentions FGFR2 is not necessarily equivalent to a validated companion diagnostic result. Clinicians should verify the alteration category, specimen type, assay performance and current prescribing information rather than relying only on a summary line in the electronic record.

Important uncertainties remain

The principal limitation is the absence of randomization. The study can estimate response frequency and durability, but it cannot determine whether lirafugratinib is superior to another FGFR inhibitor, cytotoxic therapy or supportive care. Overall survival can also be influenced by subsequent treatment and by the favorable prognostic features sometimes associated with molecularly selected disease.

Generalizability is another concern. Trial participants typically have adequate organ function and performance status, while patients in routine practice may have biliary obstruction, recurrent infection, impaired hepatic function or multiple comorbidities. The benefit-risk balance may differ in those underrepresented groups.

Longer follow-up is needed to characterize response durability, uncommon toxicities and outcomes after resistance develops. Comparative trials and translational studies are also needed to define optimal sequencing and determine whether particular FGFR2 fusion partners or co-alterations influence response.

Questions clinicians ask

Who qualifies under the FDA approval?

Eligible patients are adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma whose tumor has an FGFR2 fusion or another qualifying rearrangement detected by an FDA-approved test. The indication should not be extended automatically to FGFR2 amplification, a point mutation or a variant of uncertain significance.

Does every patient need molecular testing before lirafugratinib?

Yes. Eligibility depends on documenting the specified FGFR2 molecular event, not simply diagnosing cholangiocarcinoma. Comprehensive genomic profiling should be obtained early enough to guide treatment, with RNA-based testing or tissue reassessment considered when a DNA assay is negative or inconclusive and suspicion remains.

Can lirafugratinib be used after another FGFR inhibitor?

The strongest regulatory evidence comes from patients who had received prior systemic treatment but were FGFR inhibitor-naive. The approval does not establish the response rate after pemigatinib, futibatinib or another FGFR-directed therapy, and cross-resistance may limit benefit in that setting.

How should the response results be interpreted?

The single-arm study showed durable tumor responses, supporting activity in the selected population. Without a randomized comparator, however, the evidence cannot establish a survival advantage or show that lirafugratinib is more effective or safer than another available FGFR inhibitor.

References

1. FDA approves lirafugratinib for previously treated unresectable locally advanced or metastatic cholangiocarcinoma — U.S. Food and Drug Administration, 2026 2. Study of RLY-4008 in Patients With Unresectable Advanced or Metastatic Solid Tumors — ClinicalTrials.gov, 2020 3. Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Health Professional Version — National Cancer Institute, 2025